Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Schlumberger NV (SLB) Price & Performance

Hinge Health Inc. Class A Common StockTrade
Schlumberger NVTrade

Price performance (Past 24H)

Key statistics

Hinge Health Inc. Class A Common Stock vs Schlumberger NV — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Schlumberger NV trades at $48.43 (market cap $72.38B). The key difference: Schlumberger NV is far larger — about 8.5× Hinge Health Inc. Class A Common Stock's market cap, and Schlumberger NV pays a 2.42% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Schlumberger NV for 99 Days on average.

HNGESLB
Market Cap
$8.48B$72.38B
Volume
879,79910,231,115
Sector
HealthEnergy
52-Week High
$105.14$60.10
52-Week Low
$31.17$32.57
Typical Hold Time
0 Days99 Days
Enterprise Value
$8.10B$81.11B
Dividend Yield
—2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hinge Health Inc. Class A Common Stock

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

Schlumberger NV

SLB trades at $48.51, down 0.53% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with 8.53% net income margin and 13.37% ROE, though revenue declined slightly to $35.71B in 2025. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility. Analyst consensus remains strongly bullish with 85% buy ratings and $64.58 price target representing 33% upside potential.

SLB presents a compelling value opportunity with solid fundamentals and strong analyst support, though near-term headwinds include declining profit margins and bearish technical indicators. The company's recent major contract awards and dividend payments provide stability, but investors should monitor execution risks in international markets and potential volatility in energy sector demand.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HNGE
100% Buy0% Sell
Avg holding period · 0 Days
SLB
28% Buy72% Sell
Avg holding period · 99 Days

About Hinge Health Inc. Class A Common Stock

Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.

Read more on HNGE →

About Schlumberger NV

Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.

Read more on SLB →